Licensing, Acquisitions, and Other Arrangement- Acquisition of Gilgamesh Pharmaceuticals, Inc. (Details) - Gilgamesh Pharmaceuticals, Inc. - USD ($) $ in Millions |
3 Months Ended | |
|---|---|---|
Dec. 31, 2025 |
Oct. 01, 2025 |
|
| Collaborative and license agreements | ||
| Maximum future payments upon achievement of certain milestones | $ 300 | |
| Subsequent event | ||
| Collaborative and license agreements | ||
| Cash consideration paid to shareholders | $ 900 |
| X | ||||||||||
- Definition Represents the maximum additional payment for research and early development of collaboration projects. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|